"MAP Kinase Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44 kDa mitogen-activated protein kinase kinase with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048370
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.200 D08.811.913.696.620.682.725.200.200 D12.644.360.440.200 D12.776.476.440.200
|
| Concept/Terms |
MAP Kinase Kinase 2- MAP Kinase Kinase 2
- Kinase Activator Kinase MEK2
- MAPK-ERK Kinase 2
- MAPK ERK Kinase 2
- MAP2K2 Protein
- MAPK Extracellular Signal-Regulated Kinase 2
- MAPK Extracellular Signal Regulated Kinase 2
- Mitogen-Activated Protein Kinase Kinase 2
- Mitogen Activated Protein Kinase Kinase 2
- MEK-2 (MAPK Extracellular Signal-Regulated Kinase 2)
- MAPK Kinase 2
- MEK2 (MAPK Extracellular Signal-Regulated Kinase 2)
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 2".
This graph shows the total number of publications written about "MAP Kinase Kinase 2" by people in this website by year, and whether "MAP Kinase Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 2" by people in Profiles.
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
-
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 03; 567(7749):521-524.
-
Interaction of tRNA with MEK2 in pancreatic cancer cells. Sci Rep. 2016 06 15; 6:28260.
-
The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014 Dec; 74(18):2111-28.
-
ECM-dependent HIF induction directs trophoblast stem cell fate via LIMK1-mediated cytoskeletal rearrangement. PLoS One. 2013; 8(2):e56949.
-
Peroxisome proliferator-activated receptor a positively regulates complement C3 expression but inhibits tumor necrosis factor a-mediated activation of C3 gene in mammalian hepatic-derived cells. J Biol Chem. 2013 Jan 18; 288(3):1726-38.
-
PPAR? activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells. Biochem Biophys Res Commun. 2010 Nov 19; 402(3):477-82.
-
RasGRP1 stimulation enhances ubiquitination and endocytosis of the sodium-chloride cotransporter. Am J Physiol Renal Physiol. 2010 Aug; 299(2):F300-9.
-
Role of the nuclear receptors HNF4 alpha, PPAR alpha, and LXRs in the TNF alpha-mediated inhibition of human apolipoprotein A-I gene expression in HepG2 cells. Biochemistry. 2009 Dec 22; 48(50):11950-60.
-
Involvement of Per-Arnt-Sim Kinase and extracellular-regulated kinases-1/2 in palmitate inhibition of insulin gene expression in pancreatic beta-cells. Diabetes. 2009 Sep; 58(9):2048-58.